
Building an EHR Pathway to Support Menopause Care in Primary Care
Arina Chesnokova, MD, MPH, describes an EHR-based algorithm designed to help primary care clinicians prescribe menopause therapy safely and know when to refer.

Arina Chesnokova, MD, MPH, describes an EHR-based algorithm designed to help primary care clinicians prescribe menopause therapy safely and know when to refer.

Arina Chesnokova, MD, MPH, discusses EHR data showing menopause is rarely coded in primary care, with lower rates among racially minoritized and publicly insured women.

Linda Bradley, MD, explains why blind endometrial sampling may miss focal uterine pathology and when persistent abnormal bleeding should prompt hysteroscopy or referral.

Black and Hispanic women had higher rates of hormone therapy discontinuation in a new study. Intira Sriprasert, MD, PhD, discusses barriers and primary care interventions.

Cheryl Cox Kinney, MD, identifies VMS red flags that warrant further evaluation, including fever, weight loss, lymphadenopathy, and persistent symptoms.

Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.

TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.

TMS 2026: Approximately 21% of women initiated systemic HT after menopause, with substantial declines in treatment persistence during the first 2 years.

TMS 2026: JoAnn Pinkerton, MD, discusses elinzanetant's onset of VMS relief, common adverse effects, and treatment expectations for primary care physicians.

Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in cardiometabolic risk factors.

TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data.

TMS 2026: Only 21.7% of women initiated menopause hormone therapy, with significant racial disparities and low treatment persistence, a new study finds.

TMS 2026: Stephanie Faubion, MD, on how to identify overlooked menopause symptoms and guide hormonal or nonhormonal treatment decisions in primary care settings.

TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.

JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.

TMS 2026: Women exercising at least 5 days a week reported lower perimenopause symptom scores across psychological, somatic, and urogenital domains.

TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.

TMS 2026: Pauline Maki, PhD, discusses real-world OPTION-VMS data linking fezolinetant to improvements in menopausal VMS, depression, and anxiety symptoms.

TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.

TMS 2026: In ARIC, menopause before age 40 was linked to higher CVD and CHD risk, with insulin resistance mediating about 19% of the association.

TMS 2026: Post hoc OASIS 1 and 2 data show more women on elinzanetant reported improvement across all 8 PROMIS sleep disturbance items vs placebo at week 12.

In a pilot study of 20 midlife women with vasomotor symptoms, an AI-enabled VR program delivering CBT showed early feasibility and acceptability.

Hot flashes and night sweats are just 2 of the myriad symptoms associated with menopause. Click through a quick refresher on the transition and effective treatments.

Genitourinary symptoms of menopause often are ignored--by patients and practitioners alike. Primary care clinicians are in a key position to identify, educate, and initiate treatment.

Ruth Benca, MD, PhD, and Adam Spira, PhD, discuss how sleep disturbances, especially sleep apnea, may drive dementia risk and what to ask patients.

SLEEP 2026: A sleep expert discusses screening tools, referral pathways, and why sleep disorders matter for cardiometabolic health in primary care.

SLEEP 2026: Ashesha Mechineni, MD, discusses what the emerging pharmacotherapy pipeline means for clinicians.

Tirzepatide, nerve stimulation, and oral AD109 are reshaping OSA care as phenotyping replaces the one-size-fits-all CPAP default.

Patients with OSA who cannot tolerate CPAP may benefit from discussions about oral appliances, HNS, and other treatment options. Sairam Parthasarathy, MD, dives deeper.

SLEEP 2026: Virend Somers, MD, PhD, details how busy primary care physicians can address sleep in routine visits.